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OBJECTIVE—The RETN gene encodes the adipokine resistin.
Associations of RETN with plasma resistin levels, type 2 diabe-
tes, and related metabolic traits have been inconsistent. Using
comprehensive linkage disequilibrium mapping, we genotyped
tag single nucleotide polymorphisms (SNPs) in RETN and tested
associations with plasma resistin levels, risk of diabetes, and
glycemic traits.
RESEARCH DESIGN AND METHODS—We examined 2,531
Framingham Offspring Study participants for resistin levels,
glycemic phenotypes, and incident diabetes over 28 years of
follow-up. We genotyped 21 tag SNPs that capture common
(minor allele frequency 0.05) or previously reported SNPs at
r
2  0.8 across RETN and its ﬂanking regions. We used sex- and
age-adjusted linear mixed-effects models (with/without BMI ad-
justment) to test additive associations of SNPs with traits,
adjusted Cox proportional hazards models accounting for relat-
edness for incident diabetes, and generated empirical P values
(Pe) to control for type 1 error.
RESULTS—Four tag SNPs (rs1477341, rs4804765, rs1423096,
and rs10401670) on the 3 side of RETN were strongly associated
with resistin levels (all minor alleles associated with higher
levels, Pe0.05 after multiple testing correction). rs10401670 was
also associated with fasting plasma glucose (Pe  0.02, BMI
adjusted) and mean glucose over follow-up (Pe  0.01; BMI
adjusted). No signiﬁcant association was observed for adiposity
traits. On meta-analysis, the previously reported association of
SNP 420C/G (rs1862513) with resistin levels remained signiﬁ-
cant (P  0.0009) but with high heterogeneity across studies (P 
0.0001).
CONCLUSIONS—SNPs in the 3 region of RETN are associated
with resistin levels, and one of them is also associated with
glucose levels, although replication is needed. Diabetes 58:
750–756, 2009
A
dipose tissue is now recognized as a proliﬁc
endocrine organ. In the past few years, several
proteins, called adipokines, produced by adi-
pose tissue have been discovered (1). In the
process of unraveling the link between obesity and devel-
opment of diabetes, various adipokines have been sus-
pected to contribute to the pathogenesis of insulin
resistance. Resistin is a 12.5-kDa polypeptide that belongs
to the resistin-like molecule family of cysteine-rich pro-
teins (2). In murine models, it is produced mainly by
adipocytes, and it has been proposed to link obesity with
diabetes (3). In humans, adipocytes seem to contribute to
only a small fraction of the resistin production (4), and
macrophages are considered the predominant source of
circulating resistin (5,6). Adipose tissue of obese individ-
uals is characterized by increased inﬁltration by macro-
phages (7), which have been proposed to contribute to the
proinﬂammatory state that is characteristic of insulin
resistance. Some population studies (8–10) have shown
that resistin levels are indeed associated with metabolic
risk factors and insulin resistance, suggesting that resistin
may play an important role in the pathophysiology of
diabetes.
The gene encoding resistin (RETN) is located on chro-
mosome 19p13. Genetic variants in RETN have been
examined by many groups, and it is estimated that up to
70% of the variation in circulating resistin levels can be
explained by genetic factors (11). Several single nucleo-
tide polymorphisms (SNPs) have been associated with
resistin levels (9,12–14). However, associations between
RETN and BMI or other measures of adiposity have
shown very inconsistent results (13,15–21). Polymor-
phisms in RETN also have been associated with indexes of
insulin resistance in some reports (21,22), but lack of
replication and null associations (13,19) have raised ques-
tions regarding the robustness of these ﬁndings. Moreover,
most of the analyses examining common variation in
RETN and risk of type 2 diabetes have been negative
(9,13,16,23–27), with nominal associations only emerging
in subanalyses (28,29). The inconsistencies in those stud-
ies might be due to low power afforded by small samples
or poor coverage of the gene and of its ﬂanking sequences.
To address those limitations, we conducted ﬁne map-
ping of RETN to test if any of the SNPs in or around the
gene are associated with resistin levels, diabetes inci-
dence, or glycemic and obesity traits in the Framingham
Offspring Study, a large representative community sample.
Our goal was to conﬁrm or refute previous reports of
association and possibly uncover novel SNP associations
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RESEARCH DESIGN AND METHODS
The Framingham Offspring Study is a large community-based prospective
cohort study designed to investigate cardiovascular disease risk factors. This
analysis includes 2,531 participants (including 285 pedigrees and 1,445 unre-
lated individuals) who were followed over 28 years on a periodic basis (from
exam 1 [1971–74] up to exam 7 [1998–2001]). Each exam cycle included
anthropometric measurements, a physical exam, and blood samples related to
cardiovascular risk factors. The study was approved by the institutional
review boards of Massachusetts General Hospital, Boston University, and the
Massachusetts Institute of Technology; written informed consent, including
consent for genetic analyses, was obtained from all study participants.
Participants underwent standardized procedures for all anthropometric
measurements (weight, height, and waist circumference [at the umbilicus]).
BMI was calculated using measured weight (kg) and the square of height (m
2).
Diabetes was deﬁned by 2003 American Diabetes Association clinical criteria,
where case subjects were deﬁned as those who used oral hypoglycemic or
insulin therapy at any exam or had a fasting plasma glucose (FPG) 7.0
mmol/l at the index exam and FPG 7.0 mmol/l on at least one prior exam.
Fasting resistin levels were measured once at exam 7. For diabetes, we were
primarily interested in outcomes and metabolic traits measured over fol-
low-up (time-averaged mean FPG over follow-up [exams 3–7, chosen for
measurement stability]), and at the last follow-up (exam 7) including FPG;
fasting insulin; homeostasis model assessment of insulin resistance (HOMA-
IR) (30); A1C levels ; the Gutt 0- to 120-min insulin sensitivity index (31),
conducted in a subsample; BMI; waist circumference; visceral adipose tissue
(VAT); and subcutaneous adipose tissue (SAT), measured by computerized
tomography (the latter two conducted in a subsample) (32). FPG was
measured immediately with a hexokinase reagent kit (A-gent glucose test;
Abott, South Pasadena, CA), and A1C was measured by high-performance
liquid chromatography (33). Other plasma analyses were frozen at 80°C until
assay: fasting plasma insulin was measured with a human-speciﬁc insulin
assay (Linco, St. Louis, MO), and fasting total resistin levels were measured by
enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN). Intra-
assay coefﬁcients of variation were 3% for glucose, 6.1% for insulin, and 9.0%
for resistin.
SNP selection. We downloaded SNPs from the region of interest (20 kb on
the 5 end plus 10 kb on the 3 end of RETN) from the phase 2 HapMap
database (www.hapmap.org) in January 2006. Due to sparse coverage of the
region, we then mined the dbSNP database to choose additional SNPs across
the region so as to ensure adequate coverage. We genotyped a set of 58 SNPs
in the HapMap European-descent CEU plate, and 27 of them passed quality-
control metrics (nonmonomorphic in CEU, minor allele frequency [MAF]
0.05, and Hardy-Weinberg equilibrium [HWE] P value  0.001). We used
Tagger (www.broad.mit.edu/mpg/tagger) to select 21 tag SNPs using a pair-
wise approach to capture (with an r
2  0.8) the 27 SNPs that passed quality
control in the region of interest. Previously reported SNPs were forced in the
tagging approach.
Genotyping. Genotyping was performed on the iPLEX Sequenom platform.
To correctly estimate MAF and HWE, we performed these calculations in a
maximally unrelated subset of individuals. The genotyping success rate was
95% for all the LD-tagging SNPs (average 98.4%). Consensus rates on a
subset of 254 duplicate individuals reached 99.6%. All the SNPs met HWE (P 
0.001).
Statistical analysis. The quantitative traits were regressed against covari-
ates in order to produce Studentized residuals, which were used as the
dependent variable in the subsequent genetic models. Two covariate adjust-
ment schemes were used: the ﬁrst with sex, age, and age
2 adjustment and the
second with BMI added to age and sex to examine the strength of the SNP
associations when adjusted for overall adiposity. For resistin levels and
glucose-related traits (mean glucose exam 3–7, FPG, fasting insulin, HOMA-IR,
A1C, and Gutt 0- to 120-min insulin sensitivity index), we excluded partici-
pants with diabetes.
The association between each trait residual and each SNP was assessed
using a linear mixed-effects (LME) model implemented in SOLAR (34) to
account for the within-family correlation of the trait. Each SNP was included
in a model as a ﬁxed effect with additive coding. The models included random
effects to account for the covariance between family members; the covariance
structure was determined by the degree of relatedness between each relative
pair.
To assess SNP associations with type 2 diabetes, we used Cox proportional
hazards survival analysis, with diabetes as the outcome and the survival time
as the age at the exam at which diabetes was ﬁrst determined. The survival
time of individuals without diabetes was the age at their last exam. The model
was implemented with the survival package in R (35), with the same
adjustments as in the LME models, with covariates taken at the ﬁrst exam.
Trait correlation among siblings was modeled with a frailty term in the
survival model (36).
Statistical signiﬁcance was determined using an empirical P value (Pe)
obtained by a simulation strategy, which generated a null distribution of
minimum P values. We simulated a trait for our sample using SIMQTL in
SOLAR (34). The heritability of the trait was 35%, although similar null
distributions were obtained for heritabilities of 15 and 50%. The simulated trait
was analyzed in the same manner as the trait residuals, using LME models
implemented in SOLAR, and the minimum P value observed over all the SNPs
was recorded. A total of 10,000 traits were generated, producing an empirical
distribution of minimum P values. This strategy provides multiple SNP-testing
correction accounting for the correlation among the SNPs but does not
correct for the multiple traits being tested.
Multiple SNP models. When we observed multiple SNP associations for the
same trait, and the associated SNPs were in moderate to high LD, we
considered the possibility that the association signals were not independent.
To assess whether these association signals were simply due to LD among
the SNPs, we sequentially added SNPs to the LME models: if the signals were
independent, we expected that they would each remain signiﬁcant in these
models.
BMI interaction model. Based on a previous report (28), we assessed the
effect of a BMI  genotype interaction with SNP rs3745367 (also known as
IVS2  181G/A) in the LME model by adding a ﬁrst-level interaction term
(BMI  rs3745367) to predict diabetes incidence. Also, since the associations
of rs10401670 with glucose seemed stronger in BMI-adjusted models, we
explored the interaction of rs10401670 and BMI to predict diabetes incidence.
Meta-analysis of association between SNP 420C/G (rs1862513) and
resistin levels. The variation in RETN most often reported in the previous
literature is the promoter SNP 420C/G (rs1862513). We included rs1862513
in our tags to conﬁrm or refute previous ﬁndings with resistin levels. Since
many groups have reported associations with resistin levels, we decided to
perform a meta-analysis of our results and published reports by requesting
crude data from the corresponding authors. The meta-analyses of the rela-
tionship between rs1862513 with resistin levels were performed using the
inverse-variance method for pooling regression coefﬁcients with a random
effects estimate based on the DerSimonian-Laird method (37).
RESULTS
Characteristics of the participants genotyped in the Fra-
mingham Offspring Study are presented in Table 1. Overall,
2,531 participants were included in this analysis, 53% were
women, and 10% had a diagnosis of diabetes over the 28
years of follow-up. Mean resistin levels measured at exam
7 were 14.1  7.2 ng/dl. The heritability of resistin levels in
the Framingham Offspring Study was estimated to be 35%
(adjusted for sex, age, age
2, and BMI). Other metabolic
traits measured at exam 7 and the mean glucose levels
over exams 3–7 are presented in Table 1. Resistin levels
were modestly correlated with BMI (r  0.16), waist
circumference (r  0.18), VAT (r  0.15), and SAT (r 
0.13; all correlations age and sex adjusted; all P values 
0.001).
With 21 tag SNPs selected by a tagging approach that set
an r
2  0.8, we were able to capture 96% (26 of 27 SNPs
that passed quality control in the CEU plates) of SNPs in
the region of interest at an r
2  0.8 and 100% at an r
2  0.7
(see supplementary Table 1 for details regarding coverage
[available at http://diabetes.diabetesjournals.org/cgi/content/
full/db08-1339/DC1]). Average distance between tag SNPs
was 1.5 kb. The tag SNPs are shown in Table 2, with their
location on chromosome 19 (NCBI B35 assembly), relation
to RETN itself (in and around the gene), and other names
given in prior publications. SNP rs3745368 was not fol-
lowed further due to its low MAF (0.002) in our sample.
The LD map of the genotyped region is presented in
supplementary Fig. 1 (D statistics). RETN is a short gene
spanning only 1,369 bp. A gene coding for an open reading
frame (C19orf59) also known as mast cell–expressed
membrane protein 1 (MCEMP1) is located downstream of
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approach, with our last downstream SNP being on the 3
side of MCEMP1. The LD map for the tagging SNPs in the
Framingham population is shown in supplementary Fig. 2.
Circulating resistin levels were measured in 1,877 geno-
typed participants without diabetes. The associations for
each tag SNP with resistin levels is illustrated in Fig. 1. The
mean resistin level for each genotype and the nominal
(uncorrected) and empirical (corrected for the number of
SNPs) P values for each tag SNP are presented in Table 3.
We found that the minor alleles at four tag SNPs
(rs1477341, rs4804765, rs1423096, and rs10401670) in the
TABLE 1
Characteristics of 2,531 Framingham Offspring Study partici-
pants genotyped for RETN variants
n
Population demographic
Unrelated 1,445
Pedigrees 285
Sibpairs 989
Avuncular pairs 66
Cousins 653
Sex (% of female) 2,531 53
Exam 7 characteristics
Age (years) 2,482 61  9.6
BMI (kg/m²) 2,394 28.2  5.4
Waist circumference (inches) 2,377 39.3  5.6
VAT (cm
3) 1,018 2,139  1,100
SAT (cm
3) 1,018 2,983  1,312
Fasting blood glucose (mg/dl)* 2,198 100.3  18.0
Fasting insulin (	U/ml)* 2,158 14.5  8.4
HOMA-IR* 2,158 3.7  2.7
Gutt insulin sensitivity index* 815 21.7  7.3
A1C (%)* 2,025 5.5  0.7
Resistin levels (ng/dl)* 1,877 14.1  7.2
Longitudinal follow-up
Mean fasting glucose exams 3–7
(mg/dl)† 2,515 99.3  20.4
Diabetes (%)‡ 2,531 10
Data are means  SD or percent, unless otherwise indicated. *After
removing participants with diabetes. †Over exams 3–7 because of
stability of measurements. ‡Over exams 1–7, 28 years of follow-up on
average.
TABLE 2
Characteristics of SNPs genotyped in and around RETN in 2,543 participants in the Framingham Offspring Study
SNP
identiﬁcation
Position
(NCBI 35)
Relation to
the RETN
gene Other name Call rate HWE P Strand
Major
allele
Minor
allele MAF
rs794070 7620814 5’ of promoter 0.97 0.32  T C 0.21
rs11883223 7628636 5’ of promoter 0.99 0.11  G A 0.17
rs2081075 7629461 5’ of promoter 0.97 0.28  G A 0.29
rs10418380 7630540 5’ of promoter 0.95 0.76  A G 0.32
rs10413807 7630628 5’ of promoter 0.99 0.69  G C 0.21
rs12460483 7636594 5’ of promoter 1.00 0.71  G A 0.12
rs12459044 7638406 Promoter 0.99 0.15  C G 0.14
rs7408174 7638955 Promoter 0.97 0.54  T C 0.31
rs1862513 7639793 Promoter 420C/G 1.00 0.57  G C 0.29
rs3219177 7640369 Intron 2 IVS2  39C/T 0.99 0.35  C T 0.21
rs3745367 7640511 Intron 2 IVS2  181G/A 0.99 0.67  G A 0.24
rs3219178 7640951 Intron 3 IVS3  167C/G 0.97 1.00  C G 0.42
rs10402265 7641089 Intron 3 0.99 1.00  C G 0.14
rs3745368 7641297 3’ UTR 3’ UTR  62G/A 0.98 1.00  G A 0.002
rs3745369 7641475 3’ of 3’ UTR 0.99 0.80  G C 0.50
rs1477341 7642799 3’ of 3’ UTR 0.99 0.87  A T 0.44
rs4804765 7643840 3’ of 3’ UTR 0.98 0.64  G T 0.33
rs1423096 7645177 3’ of 3’ UTR 0.99 0.53  G A 0.09
rs10401670 7648802 3’ of 3’ UTR* 0.98 0.75  C T 0.43
rs11882592 7649975 3’ of 3’ UTR* 0.98 0.07  C A 0.18
rs10411016 7651043 3’ of 3’ UTR 0.98 0.79  T G 0.49
*Located in chromosome 19 open reading frame 59 (C19orf59), also known as mast cell–expressed membrane protein 1 (MCEMP1).
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FIG. 1. Negative log base 10 of the P value for genetic associations for
resistin levels under the additive model (left Y-axis), graphed versus
SNPs in the RETN region arranged by chromosomal position (X-axis).
The continuous line marked by the right Y-axis indicates the recombi-
nation rate. The RETN and C19orf59 (also known as mast cell–
expressed membrane protein 1 [MCEMP1]) genes are shown by the
horizontal arrows at the bottom of the plot. , traits adjusted for sex
and age; , additional adjustment for BMI.
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levels (all Pe  0.05). Since some of those SNPs were in
moderate LD in the Framingham cohort (see supplemen-
tary Table 6 for speciﬁc D and r
2 values), we conducted
multiple SNPs models. When models were examined with
various combinations of these SNPs, rs4804765 and
rs1423096 had independent associations with resistin lev-
els and rs4804765 explained the association of the two
other SNPs (rs1477341 and rs10401670). The best-ﬁtting
model included rs4804765 and rs1423096 and explained
1.5% of the variance in resistin levels.
One of these SNPs in the 3 region, rs10401670, was also
associated with mean glucose over follow-up (Pe  0.02,
after BMI adjustment Pe  0.01) and FPG at exam 7 (Pe 
0.10, after BMI adjustment Pe  0.02): its minor T allele
was associated with higher glucose levels, concordant
with a potential effect of its association with higher
resistin levels. Two other SNPs showed associations with
FPG at exam 7 (rs1423096, Pe  0.049; and rs10413807,
Pe  0.02) but did not remain signiﬁcant after adjustment
for BMI. No other associations were observed in the
glycemic or adiposity traits (Pe  0.05) (see supplemental
Table 3 for details).
Diabetes incidence was analyzed over the 28 years of
follow-up. None of the SNPs offered convincing associa-
tion with diabetes survival (all P values  0.05) (see
supplementary Table 2). Because a previous study re-
ported that IVS2  181G/A was associated with diabetes
when an interaction with BMI was added to the model
(28), we conducted diabetes incidence analysis with a BMI
interaction term included in the model for this SNP, but
even with this more reﬁned replication attempt we did not
detect a signiﬁcant association. We also explored the
effect of BMI on the association between rs10401670 and
diabetes incidence: adding a BMI  rs10401670 term to the
LME model revealed a signiﬁcant interaction (P  0.02),
and the P value for the main effect for rs10401670 reached
nominal signiﬁcance (P  0.01).
The promoter SNP 420C/G (rs1862513) has been in-
vestigated by many groups, some examining its associa-
tion with resistin levels (9,11,13,14,38) and a few with
diabetes (29,39) or adiposity (15–18). The analysis of
420C/G (rs1862513) in the Framingham Offspring Study
did not show an association with any of the traits mea-
sured, including resistin levels. To help attempt to discrim-
inate low power from a true null association, we
conducted a meta-analysis of the association of SNP
420C/G (rs1862513) with resistin levels. The details of
each population included in the meta-analysis
(9,11,13,14,38) and our results are presented in Table 4.
The minor C allele seemed to be associated with higher
resistin levels; this effect was mainly driven by the largest
Japanese study. Heterogeneity was highly signiﬁcant (P 
0.0001). The divergence between studies could be due to
differences in ethnic background, age, sex distribution,
diabetes status, or other characteristics. When we re-
moved the diabetic subjects from the analysis, heteroge-
neity was still present.
DISCUSSION
We have demonstrated that circulating resistin levels are
associated with SNPs in the 3 region of RETN (rs1477341,
rs4804765, rs1423096, and rs10401670) in a large, represen-
tative community sample. Among the four SNPs that were
associated with resistin levels, rs4804765 and rs1423096
showed independent association according to multiple
SNP models. One of those, rs10401670, was also associ-
ated with mean fasting glucose and FPG at exam 7.
Moreover, rs10401670 was nominally associated with dia-
betes incidence when including a BMI interaction term in
the model. No SNP showed signiﬁcant association with
adiposity traits.
Association with resistin and glucose levels. Previous
reports of association of SNPs within the RETN gene
region targeted speciﬁc known SNPs and thus achieved
TABLE 3
Mean circulating resistin levels per genotype at SNPs in or near RETN in the Framingham Offspring Study*
SNP
identiﬁcation
Total
N
MAF
(allele)
M/M M/m m/m
Nominal
P† Pe†
Nominal P
(BMI
adjusted)‡
Pe (BMI
adjusted)‡ n Means  SD n Means  SD n Mean  SD
rs794070 1,834 0.21 (C) 1,143 14.02  6.59 612 14.91  8.79 79 16.03  9.96 0.003 0.051 0.004 0.07
rs11883223 1,852 0.17 (A) 1,294 14.36  7.46 508 14.39  7.33 50 14.41  6.23 0.63 1.0 0.49 1.0
rs2081075 1,833 0.29 (A) 910 14.22  7.79 765 14.35  7.16 158 15.50  6.93 0.02 0.31 0.03 0.36
rs10418380 1,773 0.32 (G) 830 14.26  7.26 748 14.38  7.39 195 14.19  5.50 0.63 1.0 0.44 1.0
rs10413807 1,852 0.21 (C) 1,151 14.32  6.63 622 14.33  8.11 79 13.66  5.17 0.33 1.0 0.52 1.0
rs12460483 1,875 0.12 (A) 1,446 14.23  7.61 407 14.94  7.32 22 14.15  4.69 0.01 0.20 0.01 0.20
rs12459044 1,852 0.14 (G) 1,365 14.21  7.61 468 14.96  7.42 19 14.60  5.58 0.004 0.07 0.003 0.051
rs7408174 1,827 0.31 (C) 901 14.32  7.64 759 14.26  6.88 167 14.40  6.33 0.48 1.0 0.62 1.0
rs1862513 1,876 0.29 (C) 937 13.98  6.47 786 14.86  8.82 153 14.43  5.90 0.05 0.57 0.07 0.66
rs3219177 1,866 0.21 (T) 1,141 14.31  7.56 650 14.63  7.75 75 13.85  4.78 0.20 0.96 0.27 0.99
rs3745367 1,867 0.24 (A) 1,058 14.23  7.28 700 14.71  8.19 109 14.01  5.07 0.15 0.90 0.22 0.97
rs3219178 1,826 0.42 (G) 603 14.67  8.00 896 14.26  7.48 327 13.96  5.76 0.27 0.99 0.40 1.0
rs10402265 1,858 0.14 (G) 1,369 14.33  7.35 451 14.61  7.70 38 13.13  4.17 0.76 1.0 0.71 1.0
rs3745369 1,861 0.50 (C) 456 13.67  6.45 937 14.45  7.73 468 15.01  8.05 0.003 0.056 0.004 0.07
rs1477341 1,867 0.44 (T) 581 13.66  7.16 908 14.48  7.06 378 15.22  8.34 9.4  10
6 0.0005 7.3  10
6 0.0005
rs4804765 1,836 0.33 (T) 831 14.03  7.49 806 14.47  6.90 199 15.26  9.16 0.0010 0.02 0.0005 0.009
rs1423096 1,858 0.09 (A) 1,496 14.16  7.50 338 15.12  6.65 24 16.50  9.90 0.0007 0.01 0.0015 0.03
rs10401670 1,852 0.43 (T) 596 13.91  7.79 909 14.37  6.97 347 15.19  8.40 0.0001 0.004 5.1  10
5 0.002
rs11882592 1,843 0.18 (A) 1,273 14.39  7.51 529 14.25  6.87 41 16.66  14.03 0.71 1.0 0.67 1.0
rs10411016 1,843 0.49 (G) 475 14.64  8.53 929 14.16  6.56 439 14.48  7.73 0.76 1.0 0.86 1.0
*Resistin levels in ng/dl. †Adjustment for sex, age, and age². ‡Adjustment for sex, age, age², and BMI. M, major allele; m, minor allele.
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around the RETN gene in a large sample has allowed us to
reveal novel associations. The four SNPs associated with
resistin levels are all located in the 3 region, downstream
of RETN. SNPs outside of the coding sequence can inﬂu-
ence transcription or mRNA stability and thus affect
transcript levels. We tried to explore the functional role of
those SNPs located in the 3 region of RETN by mining
publicly available or private genome-wide expression
quantitative trait loci datasets, including one obtained
from subcutaneous and omental adipose tissue (E.E.
Schadt, personal communication). Unfortunately, the
ﬁxed marker arrays utilized in these studies do not include
our SNPs of interest or any SNPs in moderate to strong LD
with them. Thus, speciﬁc experiments will need to be
carried out to test the functional role of those SNPs on
resistin expression and regulation.
Among the SNPs in the 3 region of RETN, rs10401670 is
associated with both resistin levels and fasting glucose.
This supports the notion that resistin is implicated in
diabetes pathophysiology. Of note, rs10401670 is located
in the second intron of MCEMP1, a gene that encodes a
186–amino acid protein with a single transmembrane
domain expressed mainly by monocytes and mast cell
lines (40). Since resistin is mainly expressed by macro-
phages that evolve from monocytes in adipose tissue, it
would be interesting to know if MCEMP1 and its product
are functionally inﬂuenced by rs10401670 or the SNPs in
its 5 region and if this protein is involved in resistin and/or
glucose metabolism.
Located in the promoter region, rs1862513 (also known
as 420C/G) has been investigated by many groups. In a
meta-analysis of studies reporting resistin levels and tar-
geting this SNP, we found that the minor allele was
signiﬁcantly associated with higher resistin levels, but a
high level of heterogeneity was evident. Removing the
diabetic individuals did not eliminate heterogeneity. Re-
sidual heterogeneity could be explained by ethnic back-
ground. Indeed, the two populations of European descent
(ours and a sample from Italy) did not ﬁnd an association
between rs1862513 (420C/G) and resistin levels (11). The
other studies based on Asian populations seemed to show
a strong effect, though mainly driven by the largest Japa-
nese study (9). According to the HapMap, the MAF in
individuals from European and Japanese descent are
comparable (0.33 and 0.35, respectively), which does not
explain the difference in the studies included in our
meta-analysis. We can hypothesize that there might be
gene-gene and/or gene-environment interactions that inﬂu-
ence the two populations differently, but our data does not
allow us to make conclusions concerning those possibili-
ties. Also, rs1862513 (420C/G) might be in LD with a
causal SNP in Asians that is not present in individuals of
European descent: for example in the HapMap Japanese
JPT population, rs1862513 (420C/G) is in moderate LD
(r
2  0.58) with rs3219175 (also in the promoter region),
which is monomorphic in the HapMap CEU population.
Diabetes incidence. We did not ﬁnd a signiﬁcant associ-
ation of any SNP with diabetes incidence, although our
sample of incident case subjects was small (n  244). This
is concordant with most of the previous literature
(9,13,16,23–27). Our best P value for association with
diabetes survival (age and sex adjusted) was seen with
SNP rs3745367 (aka IVS2  181G/A; minor allele A increas-
ing the risk hazard ratio to 1.25 [1.00–1.56]), but in the
setting of multiple hypothesis, testing this nominal P value
(P  0.05) cannot convincingly be considered signiﬁcant.
Other reports testing the association between 181G/A
and diabetes have been mostly negative (23,25,26); one
report showed a positive association in the same direction
as our results when including a BMI-gene interaction term
in the model (28). Adding a BMI  genotype interaction
term to our diabetes incidence model for SNP rs3745367
did not reveal a signiﬁcant association. In contrast, adding
aB M I genotype interaction term to the model with
rs10401670 revealed signiﬁcant interaction, increasing the
signiﬁcance of the (nominal) P value of its main effect in
predicting diabetes incidence. Since we show that several
RETN SNPs are associated with circulating resistin levels
and that resistin levels are associated with insulin resis-
tance (10), it is possible that a larger sample size might
have produced an association with diabetes incidence.
Indeed, for a SNP such as rs3745367 of MAF  0.24 and
effect size  1.25, we had 40% power to detect a signiﬁcant
association with diabetes incidence (see supplemental Table
4). In examining the publicly available meta-analysis of
genome-wide association datasets DIAGRAM (http://www.
well.ox.ac.uk/DIAGRAM/meta.html), only two SNPs in the
region of interest were available (rs11883223, rs7408174)
and neither one was associated with diabetes. Unfortu-
nately, those two SNPs have very low LD with rs3745367
(r
20.10) or the other SNPs associated with resistin levels
in our ﬁndings (all r
20.02).
Adiposity traits. Reports of RETN associations with BMI
or other measures of adiposity in populations of European
descent have been inconsistent in the literature (15–20).
Some have reported no association (19), while others did
so only in subgroup analyses (15–17). The most commonly
TABLE 4
Results from meta-analysis of the association between SNP 420C/G (rs1862513) and resistin levels*
Study
Ethnic
background
Diabetes
status n Effect (95% CI) P %W (random)
Menzaghi et al. 2006 European (Italy) Nondiabetic 616 0.15 (0.52 to 0.22) 0.69 14.09
Cho et al. 2004 Korean Nondiabetic 173 3.29 (1.31–5.27) 0.001 12.54
Diabetic 411 2.54 (1.56–3.51) 5.0  10
7 13.73
Yamauchi et al. 2008 Japanese Nondiabetic 36 10.99 (4.07–17.9) 0.004 5.52
Osawa et al. 2005 Japanese Diabetic 198 4.88 (3.08–6.68) 2.9  10
7 12.80
Osawa et al. 2007 Japanese Nondiabetic 1,927 4.97 (4.59–5.34) 2.3  10
128 14.09
Diabetic 151 5.86 (4.36–7.35) 2.1  10
12 13.19
This study European (USA) Nondiabetic 2,020 0.49 (0.3–1.01) 0.05 14.03
Overall random-effects model 3.51 (1.02–6.00) 0.0009
Overall heterogeneity 0.0001
*Resistin levels in ng/dl. %W, percentage of weight accorded to the study.
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several conﬂicting reports (15–19). Our results are consis-
tent with the notion that RETN is not associated with
adiposity as assessed by BMI, waist circumference, or
body fat composition measured by computed tomography
scan. The correlation of adiposity measurements with
resistin levels, but not RETN genetic variation, suggests
that fat accumulation inﬂuences resistin levels, but RETN
variants are not likely to cause weight gain and obesity.
Strengths and limitations. Our study represents a sig-
niﬁcant advance in its comprehensive coverage of RETN
and its ﬂanking regions, moderate to high statistical power
with a large number of participants in a general commu-
nity sample including a family-based component, and
standardized phenotyping of anthropometric measure-
ments, diabetes, and metabolic traits over 28 years of
prospective follow-up. Nevertheless, this study has a few
limitations. Power for diabetes incidence was limited (see
supplemental Table 4), especially given our expectation of
small effect sizes (hazard ratio 1.4). We had adequate
power to detect a small proportion of the variance in
quantitative traits explained by common SNPs (see sup-
plementary Table 5); for example, we had 85% power to
detect 1% of the variance explained (assuming 
0.0001
and an MAF 0.05), but we may have missed smaller effect
sizes in our genotype-phenotype correlations for the resis-
tin levels or glycemic traits. Novel associations need
independent replication before we can conﬁdently claim
they represent true ﬁndings. Currently, studies with large
numbers of resistin levels measurements and custom
genotyping for comprehensive coverage are uncommon.
Also, our ﬁndings may need to be reﬁned in populations
with LD patterns that differ from those of European
descent. Finally, genetic associations do not prove that the
SNP is the direct cause of the defect; further ﬁne-mapping
and functional studies are needed to identify true causal
variants.
Conclusion. We have found that SNPs in the 3 region of
RETN are associated with circulating resistin levels in the
Framingham Offspring Study. One variant (rs10401670)
located in the 3 region of RETN, but in the second intron
of MCEMP1, is associated with both resistin levels and
fasting glucose. rs10401670 is also nominally associated
with diabetes incidence once a putative interaction with
BMI is taken into account. Functional studies are needed
to investigate the role of MCEMP1 and to test whether
these variants inﬂuence RETN expression, resistin produc-
tion, and/or glucose regulation in appropriate tissues. Our
new ﬁndings need to be replicated in independent data
before we can claim that these associations are real: it
appears that custom genotyping will be required.
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